TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
Tarsus Pharmaceuticals (NASDAQ: TARS) announced a $15 million milestone payment after Grand Pharmaceutical Group obtained NMPA approval in China for TP-03 (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tarsus Pharmaceuticals (NASDAQ: TARS) announced a $15 million milestone payment after Grand Pharmaceutical Group obtained NMPA approval in China for TP-03 (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis. The approval covers the Greater China region and triggers agreed patent-related and regulatory milestones.
Under the partnership, Tarsus may receive additional payments for regulatory milestones, China sales thresholds, and tiered royalties tied to TP-03 commercial performance in the region.
Positive
- $15M milestone payment received upon NMPA approval
- NMPA regulatory approval for TP-03 in Greater China
- Potential future revenue via sales thresholds and tiered royalties
Negative
- None.
Details
News Market Reaction – TARS
On Mar 23, the day this news came out, TARS closed 0.59% below the previous close.
Data tracked by StockTitan Argus for the Mar 23 session.
Key Figures
- Milestone payment
- $15 million
- Regulatory approval of TP-03 in China triggers payment from Grand Pharma
- 2025 XDEMVY sales
- $451.4 million
- Full-year 2025 net product sales for XDEMVY
- Q4 2025 XDEMVY sales
- $151.7 million
- Fourth quarter 2025 net product sales for XDEMVY
- Bottles delivered
- 400,000 bottles
- Approximate number of XDEMVY bottles delivered in 2025
- Payer coverage
- >90%
- XDEMVY payer coverage level reported for 2025
- Year-end cash
- $417.3 million
- Tarsus cash balance at end of 2025
- Peak sales potential
- >$2 billion
- Management’s cited peak sales potential for XDEMVY
- Patients affected
- 40 million people
- Estimated people in Greater China affected by Demodex blepharitis
Historical Context
-
Announcement of management participation in March 2026 health care conferences.
-
Reported strong 2025 XDEMVY sales, robust cash and pipeline progress.
-
Added former Allergan CEO David Pyott to Board of Directors.
-
Set date and webcast details for Q4 and full-year 2025 results.
-
Planned fireside chat at BTIG Ophthalmology Day with webcast access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
demodex blepharitis medical
ophthalmic solution medical
national medical products administration regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a
The approval was obtained by Grand Pharmaceutical Group Limited (“Grand Pharma”), Tarsus’ exclusive partner for the development and commercialization of TP-03 for the treatment of Demodex blepharitis in the Greater China region, which includes the People’s Republic of China, Hong Kong, Macau and Taiwan.
“TP-03 is once again the first and only therapy approved to address the root cause of Demodex blepharitis — marking a meaningful advance for the more than 40 million people in the region affected by this disease,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “This approval underscores our commitment to bringing this much-needed treatment to patients worldwide, and we look forward to supporting Grand Pharma as they prepare for launch.”
Under the terms of the agreement with Grand Pharma, Tarsus is eligible to receive the
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution)
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding achievement of milestone payments due Tarsus and our partners’ ability to commercialize TP-03 in the Greater China region, and the quotations of Tarsus’ management. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Important factors that could cause actual results to differ materially from those in the forward-looking statements include: Tarsus is heavily dependent on the successful commercialization of XDEMVY for the treatment of Demodex blepharitis and the successful development, regulatory approvals and commercialization of its current and future product candidates; Tarsus’ ability to obtain and maintain regulatory approval for and successfully commercialize its products, including XDEMVY for the treatment of Demodex blepharitis, and its product candidates to meet existing and future regulatory standards; Tarsus has incurred significant losses and negative cash flows from operations since inception and anticipates that it could continue to incur significant expenses and potential losses in the future; Tarsus’ capital requirements are difficult to predict and may change; Tarsus may need to obtain additional funding to achieve its goals and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force Tarsus to delay, reduce, or eliminate its product development programs, commercialization efforts or other operations; Tarsus may not ultimately be successful in educating healthcare professionals and the market about the need for treatments specifically for Demodex blepharitis and other diseases targeted by XDEMVY or our product candidates; the development and commercialization of Tarsus’ products and its product candidates is dependent on intellectual property it licenses from Elanco Tiergesundheit AG; Tarsus expects to expand its development, regulatory, operational, sales, marketing, and distribution capabilities and Tarsus may encounter difficulties in managing its growth, which could disrupt its operations; the sizes of the market opportunity for XDEMVY and Tarsus’ product candidates, particularly TP-04 for the potential treatment of ocular rosacea, as well as TP-05 for the potential prevention of Lyme disease, have not been established with precision and may be smaller than estimated, possibly materially; the results of Tarsus’ earlier studies and trials may not be predictive of future results; any termination or suspension of, or delays in the commencement or completion of, Tarsus’ planned clinical trials could result in increased costs, delay or limit its ability to generate revenue from net product sales and adversely affect its commercial prospects; if Tarsus is unable to obtain and maintain sufficient intellectual property protection for XDEMVY or its product candidates, or if the scope of the intellectual property protection is not sufficiently broad, Tarsus’ competitors could develop and commercialize products similar or identical to Tarsus’ products; and if Tarsus is unable to access capital (including but not limited to cash, cash equivalents, and credit facilities) and/or loses capital, as a result of potential failure of any financial institutions that Tarsus does business with directly or indirectly. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statements and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2025 filed on February 23, 2026, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this earnings release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
akemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.